StockNews.AISignal intelligence
TG Therapeutics, Inc. · NASDAQ · Healthcare
Browse public TGTX signals with their source context and measured market impact. Open any signal for its permanent analysis page.
TG Therapeutics reported positive Phase 1 results for subcutaneous BRIUMVI in myasthenia gravis, with 82% achieving MG-ADL MCID and an average gain over four points. The company plans a Phase 2 trial enrolling about 120 patients, signaling pipeline expansion beyond MS. A risk-on market backdrop supports the move, though extended momentum and an overbought RSI could limit near-term gains.
View signal analysisTG Therapeutics reported Phase 1 data on a high-concentration subcutaneous formulation showing >60% bioavailability relative to IV, with B-cell depletion comparable to IV and no new safety signals. Pharmacokinetic modeling supports quarterly SC dosing, and Phase 3 is fully enrolled. Topline data are expected late 2026 or early 2027, with regulatory approval potential by 2028, expanding the addressable market.
View signal analysisTGTX shares rose 6.60% post-revenue estimate announcement. Projected Q4 revenue for Briumvi is approximately $182 million. Total 2025 revenue is expected to reach $616 million. 2026 revenue targets set between $875 and $900 million. CEO emphasizes significant market share for Briumvi.
View signal analysisTGTX reported Q1 earnings per share of 3 cents, missing expectations. Sales reached $120.86 million, exceeding consensus of $118.43 million. Briumvi's U.S. net sales were $119.7 million, reflecting strong market adoption. Long-term projections for Briumvi revenue increased to $560 million for 2025. Stock fell 13.2% despite positive sales growth and future forecasts.
View signal analysisTGTX shares remain in an uptrend, signaling potential for continued gains. Recent breakout indicates bullish implications for TGTX stock. Resistance at $36.25 has been broken, enhancing upward momentum. Demand may drive the price higher as sellers exit the market. Trading activity is subdued, but bullish outlook persists.
View signal analysis